Atjaunināt sīkdatņu piekrišanu

E-grāmata: Cancer-Targeted Drug Delivery

Edited by
Citas grāmatas par šo tēmu:
  • Formāts - PDF+DRM
  • Cena: 237,93 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
Citas grāmatas par šo tēmu:

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

This detailed volume explores the frontiers of tumor targeting approaches in the field of tumor-targeted drug delivery and cancer therapy. Several topics involve the improvement of cancer detection and treatment using nanotechnologies, where the main challenge to transition from the laboratory to the clinic, with more effective, targeted, and less invasive treatments. Written for the Methods in Pharmacology and Toxicology series, chapters provide the kind of detailed implementation advice needed for successful future studies.





 





Authoritative and innovative, Cancer-Targeted Drug Delivery serves as the ideal reference for researchers using current cutting-edge technologies for tumor-targeting of drugs.

Application of Graphene Oxide in Tumor Targeting and Tumor Therapy.- Antitumoral Effect on Liver Cancer of a Tumor Penetrating and Interfering Peptide.- Computer-Aided Design for Cancer-Targeted Peptide Drugs.- Advances in the Manufacturing of CAR-NK Cells for Cancer Immunotherapy.- Addressing the Blood-Brain Barrier: Overcoming Glioblastoma Drug Delivery.- Advances in Cancer Gene Therapy: Strategies, Delivery Methods, and Challenges.- Targeted Tumor Delivery Using Extracellular Vesicles.- Peptide-Assisted CRISPR/Cas9 Delivery to Tumors.- Identification of Organ- and Disease-Specific Homing Peptides Using In Vivo Peptide Phage Display.- Cancer Vaccines.

Ülo Langel is Professor Emeritus at the Department of Biochemistry and Biophysics, Stockholm University, and at the Institute of Technology, University of Tartu. His professional experience includes a career at the University of Tartu, Tartu, Estonia (from Junior Research Fellow to Associate Professor, Visiting Professor and Professor, 1974-present); The Scripps Research Institute, La Jolla, CA, USA (Associate Professor and Adjunct Professor, 2000-present); and Stockholm University, Stockholm, Sweden (from Research Fellow to Associate Professor, Professor and Chairman, 1987-present). He is an Honorary Professor at the University of Ljubljana, Ljubljana, Slovenia. He was Chairman of the Board of small companies Cepep (Sweden) and Pepfex (Sweden) and a member of the Board of Orexo (Sweden). In 2013, he was elected a member of the Academia Europaea and, in 2015, a foreign member of the Estonian Academy of Sciences. He has been awarded the Order of the White Star, 4th class, by the Republic of Estonia. He has been an invited lecturer at numerous international conferences and is a co-author of more than 490 scientific articles and 20 approved or pending patents. His research interest is in neurochemistry of neuropeptide receptors and in drug delivery by cell-penetrating peptides.